Prelude Capital Management’s Protalix BioTherapeutics PLX Stock Holding History

Prelude Capital Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$52.9K	Buy	22,700 +3,800	+20%	+$8.05K	﹤0.01%	1169
2026 Q1	$41K	Sell	18,900 -3,343	-15%	-$8.3K	﹤0.01%	1137
2025 Q4	$40K	Sell	22,243 -27,548	-55%	-$56.3K	﹤0.01%	1247
2025 Q3	$111K	Sell	49,791 -6,264	-11%	-$10.2K	0.01%	1043
2025 Q2	$83K	Buy	+56,055	New	+$115K	0.01%	933
2017 Q3	–	Sell	-200	Closed	-$2K	–	1847
2017 Q2	$2K	Buy	+200	New	+$1.88K	﹤0.01%	1530
2017 Q1	–	Sell	-1,050	Closed	-$5K	–	1721
2016 Q4	$5K	Buy	+1,050	New	+$4.69K	﹤0.01%	1437
2016 Q3	–	Sell	-10	Closed	–	–	1763
2016 Q2	$0	Buy	+10	New	+$80	﹤0.01%	1697

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SWP

Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Prelude Capital Management's PLX Position: Q2 2026 in Review

Prelude Capital Management increased its Protalix BioTherapeutics (PLX) stake by 20% in Q2 2026, buying an estimated $8.05K and bringing the position to 22,700 shares worth $52.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

Prelude Capital Management first reported a position in PLX in Q2 2016 and has held it in 8 quarters since. The position peaked at $111K in Q3 2025. 101 funds tracked by Wall St. Rank hold PLX as of Q2 2026.

Prelude Capital Management held 22,700 shares of Protalix BioTherapeutics worth $52.9K as of Q2 2026.
Prelude Capital Management bought 3,800 Protalix BioTherapeutics shares in Q2 2026, an estimated $8.05K.
Protalix BioTherapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q2 2026, its #1169 holding.
Prelude Capital Management first reported a position in Protalix BioTherapeutics in Q2 2016 and has held it in 8 quarters since.
Prelude Capital Management's Protalix BioTherapeutics position peaked at $111K in Q3 2025.
101 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.